Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus HIPPURAN I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus HIPPURAN I 131.
FLUORODOPA F18 vs HIPPURAN I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical